Download PDF
Dialyse aktuell 2021; 25(09): 366-370
DOI: 10.1055/a-1557-5104
Schwerpunkt
Nephrologie

Langzeitsicherheit von Blutdrucksenkern

Erhöhen blutdrucksenkende Medikamente das Risiko für Tumorerkrankungen?
Markus van der Giet
1   Hochdruckzentrum, Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivtherapie, Charité – Universitätsmedizin Berlin
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Eine optimale Blutdruckeinstellung ist essenziell, um langfristig kardiorenovaskuläre Schäden zu verhindern und um die kardiovaskuläre Mortalität der Patienten zu reduzieren. Viele blutdrucksenkende Medikamente wurden in den letzten Jahrzehnten sehr erfolgreich entwickelt. Patienten müssen diese z. T. für viele Jahre einnehmen, daher erwartet man von den Medikamenten eine sehr hohe Langzeitsicherheit. Das bedeutet, dass es auch nach Jahrzehnten nicht zu unangenehmen Folgeschäden wie v. a. Krebserkrankungen kommen darf. Denn es gab immer wieder Hinweise, dass bestimmte Medikamente wie Thiaziddiuretika oder auch ACE-Hemmer (ACE: „angiotensin converting enzyme“) das Wachstum spezifischer Krebserkrankungen ggf. steigern oder auch die Entstehung von Tumoren auslösen können. Dieser Beitrag fasst den aktuellen Stand zu Langzeitsicherheit bzw. -nebenwirkungen der typischen Blutdrucksenker wie ACE-Hemmer, Sartane, Kalziumantagonisten, Beta-Blocker und Diuretika zusammen.



Publication History

Article published online:
16 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Sipahi I, Debanne SM, Rowland DY. et al Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-636
    CrossrefPubMedSearch in Google Scholar
  • 2 ARB Trialists Collaboration Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals J Hypertens 2011 29. 623-635
    CrossrefPubMed
  • 3 Pottegård A, Pedersen SA, Schmidt SAJ. et al Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018; 178: 1120-1122
    CrossrefPubMedSearch in Google Scholar
  • 4 Pottegård A, Hallas J, Olesen M. et al Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282: 322-331
    CrossrefPubMedSearch in Google Scholar
  • 5 Gandini S, Palli D, Spadola G. et al Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018; 122: 1-9
    CrossrefPubMedSearch in Google Scholar
  • 6 Kristensen KB, Hicks B, Azoulay L. et al Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study. Circ Cardiovasc Qual Outcomes 2021; 14: e006687
    CrossrefPubMedSearch in Google Scholar
  • 7 Copland E, Canoy D, Nazarzadeh M. et al Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol 2021; 22: 558-570
    CrossrefPubMedSearch in Google Scholar
  • 8 SOLVD Investigators Yusuf S, Pitt B. et al Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
    CrossrefPubMedSearch in Google Scholar
  • 9 Bangalore S, Kumar S, Kjeldsen SE. et al Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82
    CrossrefPubMedSearch in Google Scholar
  • 10 Lever AF, Hole DJ, Gillis CR. et al Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998; 352: 179-184
    CrossrefPubMedSearch in Google Scholar
  • 11 Hicks BM, Filion KB, Yin H. et al Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018; 363: k4209
    CrossrefPubMedSearch in Google Scholar
  • 12 Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 1991; 51: 3621-3623
    PubMedSearch in Google Scholar
  • 13 Ager EI, Neo J, Christophi C. The reninangiotensin system and malignancy. Carcinogenesis 2008; 29: 1675-1684
    CrossrefPubMedSearch in Google Scholar
  • 14 Volpe M, Azizi M, Danser AH. et al Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur Heart J 2011; 32: 19-22
    CrossrefPubMedSearch in Google Scholar
  • 15 Pfeffer MA, Swedberg K, Granger CB. et al Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766
    CrossrefPubMedSearch in Google Scholar
  • 16 Gold B, Mirvish SS. N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide. Toxicol Appl Pharmacol 1977; 40: 131-6
    CrossrefPubMedSearch in Google Scholar
  • 17 Corrao G, Scotti L, Bagnardi V. et al Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2007; 2: 125-133
    CrossrefPubMedSearch in Google Scholar
  • 18 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002 288. 2981-2997
    CrossrefPubMed
  • 19 Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol 2016; 34: 571-581
    CrossrefPubMedSearch in Google Scholar
  • 20 Jensen AØ, Thomsen HF, Engebjerg MC. et al Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99: 1522-1528
    CrossrefPubMedSearch in Google Scholar
  • 21 Schmidt SA, Schmidt M, Mehnert F. et al Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol 2015; 29: 1545-1554
    CrossrefPubMedSearch in Google Scholar
  • 22 Pedersen SA, Gaist D, Schmidt SAJ. et al Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78: 673-681.e9
    CrossrefPubMedSearch in Google Scholar
  • 23 Faconti L, Ferro A, Webb AJ. et al Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. J Hum Hypertens 2019; 33: 257-258
    CrossrefPubMedSearch in Google Scholar
  • 24 Pahor M, Guralnik JM, Ferrucci L. et al Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497
    CrossrefPubMedSearch in Google Scholar
  • 25 Li CI, Daling JR, Tang MT. et al Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013; 173: 1629-1637
    CrossrefPubMedSearch in Google Scholar
  • 26 Azoulay L, Soldera S, Yin H. et al Use of calcium channel blockers and risk of breast cancer: A population-based cohort study. Epidemiology 2016; 27: 594-601
    CrossrefPubMedSearch in Google Scholar
  • 27 Zhang D, Ma QY, Hu HT. et al β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther 2010; 10: 19-29
    CrossrefPubMedSearch in Google Scholar
  • 28 MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results BMJ 1992 304. 405-412
    CrossrefPubMed
  • 29 Messerli FH, Bangalore S, Bavishi C. et al Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use?. J Am Coll Cardiol 2018; 71: 1474-1482
    CrossrefPubMedSearch in Google Scholar